TY - THES ID - 137951202 TI - Perceval® sutureless aortic valve replacement: Single-center experience and 10-year follow - up in 334 consecutive patients AU - Eurlings, Roxanne AU - Meuris, Bart. AU - Oosterlinck, Wouter AU - KU Leuven. Faculteit Geneeskunde. Opleiding Master in de biomedische wetenschappen (Leuven) PY - 2018 PB - Leuven KU Leuven. Faculteit Geneeskunde DB - UniCat UR - https://www.unicat.be/uniCat?func=search&query=sysid:137951202 AB - Objective. This study investigates the long-term behaviour of the Perceval® sutureless aortic bioprothesis over a period up to ten years. Echocardiographic data were collected for a single centre study cohort of 334 patient. Follow - up was completed for 99.10 % of the patients. Methods. From September 2007 until December 2016, 334 patients underwent aortic valve replacement (AVR) with the sutureless Perceval® aortic bioprothesis at the University Hospital of Leuven (UZ Leuven). The mean age of the patients was 79.3 + 5.1 years, 60.8 % were female and the mean European System for Cardiac Operative Risk Evaluation (EuroSCORE) II was 5.8 % + 5.5. Results. The 30-day mortality rate was 2.4 % (8 out of 334). 7 patients (2.1 %) suffered from postoperative stroke within 30 days after valve implantation. No patients needed short-term additional valve surgery. The mean follow - up time was 2.3 + 1.9 years (ranging from 14.2 days to 9.6 years). 5 patients suffered from endocarditis and required valve explantation. No structural valve deterioration was seen. The mortality rate after one year was 8.8 %, after two years this was 14.1 %. The peak pressure gradient was 23.5 (+10.5) mmHg and the mean pressure gradient at follow - up was 13.9 (+ 6.8) mmHg. The mean left ventricular ejection fraction at follow - up was 56.3 %. Conclusion. The results obtained in this study show a low mortality rate, both on short and on long-term and reasonable haemodynamic outcomes, meaning the Perceval® aortic bioprothesis is a valid alternative for patients with a high-risk profile in need of AVR. ER -